Off-label use of rituximab in systemic rheumatic diseases: case series

Filipe Araújo, Inês Silva, Alexandre Sepriano, Patrícia Nero, Jaime Branco

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)
50 Downloads (Pure)


B-cells play an important role not only in cellular but also in humoral immunity through differentiation into plasma cells and antibody production. B-cell depletion may, theoretically, change the course of systemic rheumatic diseases (SRD) in which self-reactive antibodies are part of the pathogenic pathway In Rheumatology, anti-B-cell antibody Rituximab is currently licensed for the treatment of rheumatoid arthritis, however there is growing evidence of its potential use in other SRD. The authors present a case series of eight patients in which Rituximab was used off-label including overlap syndrome Rhupus, systemic lupus erythematosus and Wegener's granulomatosis. In the end, a brief literature review about this subject is performed.
Original languageEnglish
Pages (from-to)290-294
Number of pages5
JournalActa reumatologica portuguesa
Issue number4
Publication statusPublished - Oct 2013


  • Rhupus
  • Systemic Lupus Erythematosus
  • Wegener’s granulomatosis
  • Rituximab
  • Off-label


Dive into the research topics of 'Off-label use of rituximab in systemic rheumatic diseases: case series'. Together they form a unique fingerprint.

Cite this